Marco Santagostino

USPTO Granted Patents = 37 (Patent Applications = 7)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 11 (Patent Applications = 7)

Average Co-Inventor Count = 6.4

ph-index = 6

Forward Citations = 133(Granted Patents)

Location History:

Mittlebiberach, DE (2007)
Magenta, IT (1996 - 2010)
Mittelbiberach, DE (2008 - 2023)

Company Filing History:

27 out of 1,535

Boehringer Ingelheim International Gmbh

patents

5 out of 36

Centrexion Therapeutics Corporation

patents

5 out of 343

Sigma-tau Industrie Farmaceutiche Riunite S.p.a.

patents

Years Active: 1996-2025

Loading Chart...

37 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12209094 - CCR2 receptor antagonists and uses thereof (2025-01-28),

2. 11814380 - Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors (2023-11-14),

3. 11731981 - CCR2 receptor antagonists and uses thereof (2023-08-22),

4. 11053237 - Process for the manufacture of 6-alkynyl-pyridine derivatives (2021-07-06),

5. 11046706 - CCR2 receptor antagonists and uses thereof (2021-06-29),

6. 10196402 - CCR2 receptor antagonists and uses thereof (2019-02-05),

7. 9670222 - CCR2 receptor antagonists and uses thereof (2017-06-06),

8. 9233950 - Co-crystals and salts of CCR3-inhibitors (2016-01-12),

9. 9051289 - Process and intermediates for preparing GPR40 agonists (2015-06-09),

10. 8993753 - Stereoselective synthesis of bicyclic heterocycles (2015-03-31),

11. 8765949 - CCR2 receptor antagonists and uses thereof (2014-07-01),

12. 8742115 - Co-crystals and salts of CCR3-inhibitors (2014-06-03),

13. 8658790 - Stereoselective synthesis of bicyclic heterocycles (2014-02-25),

14. 8394791 - Crystalline, enantiomerically pure salt form of a beta-agonist, and the use thereof as a drug (2013-03-12),

15. 7985747 - Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions (2011-07-26),

Title: Marco Santagostino: Pioneering Inventor Pushing Technological Boundaries

Introduction:

Marco Santagostino is a visionary inventor based in Mittelbiberach, Germany, whose passion for innovation and relentless pursuit of excellence have made him a prominent figure in the world of technology. With 36 patents to his name, Santagostino continues to inspire future generations of inventors to think outside the box and strive for greatness.

Latest Patents:

Among his latest patents are groundbreaking inventions such as "Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors," which have potential applications in the treatment and prevention of oncological diseases. Additionally, his work on "CCR2 receptor antagonists" offers new possibilities for treating pulmonary conditions like asthma and COPD.

Career Highlights:

Throughout his career, Marco Santagostino has made significant contributions to the field of technology. He has worked with esteemed companies such as Boehringer Ingelheim International GmbH and Sigma-tau Industrie Farmaceutiche Riunite S.p.A., where he has played a key role in driving innovation and developing cutting-edge solutions.

Collaborations:

Santagostino's collaborative spirit and expertise have led him to work closely with accomplished colleagues such as Philipp Lustenberger and Klaus Rudolf. Together, they have embarked on projects that have pushed the boundaries of what is possible in the world of technology.

Conclusion:

In conclusion, Marco Santagostino's unwavering dedication to innovation and his remarkable track record of success make him a true trailblazer in the field of technology. His pioneering inventions and collaborative efforts serve as a testament to his commitment to driving progress and shaping the future of technological advancements.

This text is generated by artificial intelligence and may not be accurate.